Pindolol – Kodiac biolabs

Plain-language summaryIntrigue 48 / 100

Pindolol is an old beta-blocker, FDA-approved in 1982, that lowers blood pressure by quieting the heart. What makes it interesting outside cardiology is a side activity: it binds tightly to a serotonin receptor (5-HT1A) that normally throttles serotonin release. By turning off that throttle alongside an SSRI antidepressant, pindolol was hypothesized to make the SSRI kick in faster (days rather than weeks). Trials produced mixed results, with some studies showing accelerated response in depression and others showing nothing. It is still used occasionally in psychiatry as an SSRI booster, but never became standard practice. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

37/100

Old beta-blocker with real 5-HT1A probe value, but inconsistent clinical signal limits excitement

Look, pindolol is one of those compounds where the mechanism is more interesting than the compound itself. Approved for hypertension in 1982, it spent years as a fairly unremarkable non-selective beta-blocker until researchers noticed something: it binds 5-HT1A receptors with real affinity (Ki around 50 nM) and acts as a partial agonist there. That property got it drafted into psychiatric research as an SSRI augmentor in the 1990s, and for a while it was genuinely intriguing.

The hypothesis was elegant. SSRIs lose their first two weeks to autoreceptor-mediated negative feedback at the raphe. Add a 5-HT1A partial agonist like pindolol, and you desensitize those presynaptic autoreceptors faster, in theory compressing the latency to antidepressant effect. Multiple placebo-controlled trials tested this through the late 1990s and into the 2000s. Some showed a real 1-2 week acceleration. Others did not. The meta-analyses are frustrating reading: positive signal on onset, weaker or null signal on overall efficacy. That inconsistency is the core problem with this compound as a research target, and we think it explains why the field mostly moved on.

Where pindolol still earns its place in a serious library is as a probe. Its specific combination of beta-blockade plus 5-HT1A partial agonism is hard to replicate with other tools. If you’re running mechanistic work on presynaptic serotonin autoreceptor desensitization, or trying to parse the cardiovascular from the serotonergic components of a drug interaction, pindolol gives you a handle thats difficult to replace. Its been called the canonical 5-HT1A binding beta-blocker in mechanism studies for good reason. Buspirone is more selective at 5-HT1A but lacks the beta component entirely. That combination makes pindolol genuinely useful for dissecting receptor contributions in mixed-pharmacology contexts.

What we dont love: the SSRI augmentation question is basically settled as disappointing, the compound is old enough that most interesting questions about it have been asked, and the short half-life (3-4 hours) is a practical nuisance in research designs. Its not a novel mechanism, not a novel compound, and the translational arrow from preclinical to clinical is pointing in different directions depending on which trial you read.

Honestly, if youre building a research program around serotonin autoreceptor biology and need a pharmacological tool with a specific dual profile, pindolol is worth having. As a primary research target in its own right? The case is thin. The probe utility is real but narrow, and the clinical inconsistency means the translational story never really closed.

Novelty: 20
Mechanism promise: 42
In-category differentiation: 35
Evidence quality: 45
Translational signal: 35
Research bench value: 52

Rationale Pindolol scores as a niche probe because its 5-HT1A autoreceptor work is genuinely useful for serotonin pharmacology, but the compound is a 1982 FDA approval with mixed augmentation trial data; bench utility saves it from obscurity, novelty and translational inconsistency drag the overall down.

Non-selective beta-adrenergic antagonist with 5-HT1A partial agonism

A non-selective beta-blocker with intrinsic 5-HT1A partial agonism; investigated as an SSRI augmenting agent.

Abstract

Pindolol (1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; CAS 13523-86-9; molecular formula C14H20N2O2; molecular weight 248.32) is a non-selective beta-adrenergic antagonist with intrinsic sympathomimetic activity (partial agonism) and 5-HT1A partial agonism, approved by the FDA in 1982. The compound’s distinguishing pharmacological feature in psychiatric research is high-affinity 5-HT1A binding (Ki approximately 50 nM) with partial agonist activity at presynaptic autoreceptors; concurrent administration with an SSRI desensitizes the autoreceptor more rapidly than the SSRI alone, hypothetically accelerating the antidepressant response. Multiple placebo-controlled trials in the 1990s and 2000s reported faster onset (1 to 2 weeks shorter latency) but inconsistent overall efficacy improvement. Plasma half-life is 3 to 4 hours; metabolism is hepatic. Approved indications in cardiology include hypertension and angina; the SSRI augmentation use remains off-label. Used as the canonical 5-HT1A binding beta-blocker in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-257Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.